Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
10 May 2022
New chemo-free triplet regimen shows promise for endometrial cancer
A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.
New chemo-free triplet regimen shows promise for endometrial cancer
09 May 2022
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
06 May 2022
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.